Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease

findings from the CKD-JAC study

Kosaku Nitta, Satoshi Iimuro, Enyu Imai, Seiichi Matsuo, Hirofumi Makino, Tadao Akizawa, Tsuyoshi Watanabe, Yasuo Ohashi, Akira Hishida

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined. Methods: We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD. Results: We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463–3.822; P = 0.0004], body mass index (OR 1.108; 95% CI 1.046–1.173; P = 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005–1.369; P = 0.0433), urinary albumin (OR 1.425; 95% CI 1.028–1.974; P = 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989–0.999; P = 0.0174). Conclusion: The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalClinical and Experimental Nephrology
DOIs
Publication statusAccepted/In press - Jun 27 2018

Fingerprint

Left Ventricular Hypertrophy
Chronic Renal Insufficiency
Odds Ratio
Blood Pressure
Dialysis
Albumins
Diabetes Mellitus
Japan
Body Mass Index
Cohort Studies
Cardiovascular Diseases
Multivariate Analysis
Cholesterol
Confidence Intervals
Kidney
Serum

Keywords

  • Albuminuria
  • Antihypertensive agent
  • Body mass index
  • Chronic kidney disease
  • Hypertension
  • Left ventricular hypertrophy
  • Mineral metabolism

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease : findings from the CKD-JAC study. / Nitta, Kosaku; Iimuro, Satoshi; Imai, Enyu; Matsuo, Seiichi; Makino, Hirofumi; Akizawa, Tadao; Watanabe, Tsuyoshi; Ohashi, Yasuo; Hishida, Akira.

In: Clinical and Experimental Nephrology, 27.06.2018, p. 1-14.

Research output: Contribution to journalArticle

Nitta, Kosaku ; Iimuro, Satoshi ; Imai, Enyu ; Matsuo, Seiichi ; Makino, Hirofumi ; Akizawa, Tadao ; Watanabe, Tsuyoshi ; Ohashi, Yasuo ; Hishida, Akira. / Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease : findings from the CKD-JAC study. In: Clinical and Experimental Nephrology. 2018 ; pp. 1-14.
@article{e7fc3e8ffd464c10a020e6f6eb4ccabb,
title = "Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study",
abstract = "Background: Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined. Methods: We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD. Results: We analyzed the baseline characteristics in 1088 participants (male 63.8{\%}, female 36.2{\%}). Diabetes mellitus was the underlying disease in 41.7{\%} of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4{\%} of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95{\%} confidence interval ([CI) 1.463–3.822; P = 0.0004], body mass index (OR 1.108; 95{\%} CI 1.046–1.173; P = 0.0005), systolic blood pressure (OR 1.173; 95{\%} CI 1.005–1.369; P = 0.0433), urinary albumin (OR 1.425; 95{\%} CI 1.028–1.974; P = 0.0333), and serum total cholesterol level (OR 0.994; 95{\%} CI 0.989–0.999; P = 0.0174). Conclusion: The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.",
keywords = "Albuminuria, Antihypertensive agent, Body mass index, Chronic kidney disease, Hypertension, Left ventricular hypertrophy, Mineral metabolism",
author = "Kosaku Nitta and Satoshi Iimuro and Enyu Imai and Seiichi Matsuo and Hirofumi Makino and Tadao Akizawa and Tsuyoshi Watanabe and Yasuo Ohashi and Akira Hishida",
year = "2018",
month = "6",
day = "27",
doi = "10.1007/s10157-018-1605-z",
language = "English",
pages = "1--14",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease

T2 - findings from the CKD-JAC study

AU - Nitta, Kosaku

AU - Iimuro, Satoshi

AU - Imai, Enyu

AU - Matsuo, Seiichi

AU - Makino, Hirofumi

AU - Akizawa, Tadao

AU - Watanabe, Tsuyoshi

AU - Ohashi, Yasuo

AU - Hishida, Akira

PY - 2018/6/27

Y1 - 2018/6/27

N2 - Background: Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined. Methods: We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD. Results: We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463–3.822; P = 0.0004], body mass index (OR 1.108; 95% CI 1.046–1.173; P = 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005–1.369; P = 0.0433), urinary albumin (OR 1.425; 95% CI 1.028–1.974; P = 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989–0.999; P = 0.0174). Conclusion: The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.

AB - Background: Although left ventricular hypertrophy (LVH) has been established as a predictor of cardiovascular events in chronic kidney disease (CKD), the relationship between the prevalence of LVH and CKD stage during the pre-dialysis period has not been fully examined. Methods: We measured left ventricular mass index (LVMI) in a cross-sectional cohort of participants in the Chronic Kidney Disease Japan Cohort (CKD-JAC) study to identify factors that are associated with increased LVMI in patients with stage 3–5 CKD. Results: We analyzed the baseline characteristics in 1088 participants (male 63.8%, female 36.2%). Diabetes mellitus was the underlying disease in 41.7% of the patients, and mean age was 61.8 ± 11.1 years. LVH was detected in 23.4% of the patients at baseline. By multivariate logistic analysis, independent risk factors for LVH were past history of cardiovascular disease [odds ratio (OR) 2.364; 95% confidence interval ([CI) 1.463–3.822; P = 0.0004], body mass index (OR 1.108; 95% CI 1.046–1.173; P = 0.0005), systolic blood pressure (OR 1.173; 95% CI 1.005–1.369; P = 0.0433), urinary albumin (OR 1.425; 95% CI 1.028–1.974; P = 0.0333), and serum total cholesterol level (OR 0.994; 95% CI 0.989–0.999; P = 0.0174). Conclusion: The cross-sectional baseline data from the CKD-JAC study shed light on the association between LVH and risk factors in patients with decreased renal function. Further longitudinal analyses of the CKD-JAC cohort are needed to evaluate the prognostic value of LVH in CKD patients.

KW - Albuminuria

KW - Antihypertensive agent

KW - Body mass index

KW - Chronic kidney disease

KW - Hypertension

KW - Left ventricular hypertrophy

KW - Mineral metabolism

UR - http://www.scopus.com/inward/record.url?scp=85049066785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049066785&partnerID=8YFLogxK

U2 - 10.1007/s10157-018-1605-z

DO - 10.1007/s10157-018-1605-z

M3 - Article

SP - 1

EP - 14

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

ER -